Probiotics in Obesity Management
Efficacy and Safety of Pasteurized Akkermansia Muciniphila Akk11 in Obesity/Overweight Weight Management and Energy Metabolism:a Randomized, Double-blind, Placebo-controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Henan
-
Luoyang, Henan, China, 471000
- The School of Food and Bioengineering, Henan University of Science and Technolog
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- A body mass index (BMI) of 24 kg/m² or above;
- Voluntarily signing an informed consent form to take part in the study;
- Willingness to undertake the study protocol and associated restrictions, such as adhering to a calorie - restricted - low carbohydrate diet;
- No intention to become pregnant from 14 days before screening, and commitment to using effective contraception until six months after the trial concludes.
Exclusion Criteria:
- Intake of products akin to the test product in the recent period that might sway the outcomes;
- Presence of mental or neurological disorders, celiac disease, lactose intolerance, or allergic conditions;
- Being pregnant, breastfeeding, or planning to conceive;
- Past diagnosis of Irritable Bowel Syndrome, Ulcerative Colitis, Hepatic Cirrhosis, or Diabetes Mellitus;
- Use of antibiotics in the preceding three months;
- Inability to comply with the test product regimen or attend follow-up visits regularly, making efficacy assessment unfeasible;
- Smoking in excess of 10 cigarettes daily;
- Hypersensitivity to probiotic products;
- Any other participants deemed unsuitable for the research by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Probiotic group
Pasteurized Akkermansia muciniphila Akk11 capsule, 100 billion TFU/day
|
The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)
|
|
Placebo Comparator: Placebo group
Placebo capsule, one capsule/day
|
The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body weight before and after intervention
Time Frame: Week 0 , Week 4, Week 8, Week 12
|
Measured using a calibrated scale
|
Week 0 , Week 4, Week 8, Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WK20250424
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.